FOSUN PHARMA

Investor Presentation

2021 Interim Report

Prepared in accordance with China Accounting Standards

Disclaimer

This document has been prepared by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the “Company”) and is for presentation use only. Copying, reproduction or redistribution of this document to any person is strictly prohibited. The information contained in this document has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The purpose of this document is not for a complete or full analysis of any financial or trading position or prospect, and any person who will be in possession of this document shall be aware that no reliance should be placed on any content contained herein. The information and opinions contained in this document are subject to change without notice, nor will the document be updated to reflect any developments which may occur after the date of this document. The Company or any of its affiliates, advisors or representatives shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

This document contains forward-looking statements that are subject to assumptions, risks and uncertainties. These forward-looking statements are generally expressed in forward-looking expressions, such as expectations, estimation, planning, projections, goals, possibilities, probabilities or so on to reflect the actions that the Company expect to or may take in the future or the results from these actions. You should not place undue reliance on these forward-looking statements. Actual results may differ from these forward-looking statements.

This document is for review only by persaons who are (i) a ''qualified institutional buyer'' ("QIB") as defined under Rule 144A under the U.S. Securities Act of 1933, as amended (the "Securities Act") in the United States; or (ii) outside the United States as defined under Regulation S under the Securities Act. By your acceptance of this presentation, you acknowledge that you satisfy the requirements and conditions set forth in the preceding sentence. The distribution of this document in any jurisdiction may be restricted by laws, and persons into whose possession it comes must inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the federal securities laws of the United States and the laws of other jurisdictions.

This document is not intended to constitute an offer to, or a solicitation for offer to, sell, purchase or subscribe for any securities nor shall it or any part of it form the basis of or being relied on for any contracts or promises.

NO SECURITIES OF THE COMPANY MAY BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS OF THE UNITED STATES. THE SECURITIES TO BE OFFERED BY THE COMPANY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR ANY STATE SECURITIES LAWS OF THE UNITED STATES. THIS PRESENTATION MATERIAL DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF THE SECURITIES ACT.

FOSUN PHARMA
Innovation for Good Health

Contents



FOSUN PHARMA
Innovation for Good Health

Business Highlights

Strategy Implementation

R&D

- Yi Kai Da® (Axicabtagene Ciloleucel Injection, US trade name: Yescarta®) is the **first CAR-T cell therapy approved in China**.
- Hong Kong, Macau and Taiwan ordered over 20 million doses of mRNA vaccine in total. Entered into a Term Sheet with BioNTech in relation to the proposed setting up of **Joint Venture** for **manufacturing and commercialization of the COVID-19 Vaccine.**
- Henlius's HLX10 for MSI-H indication **was granted priority review for commercialization by NMPA.**

Business Integration

- **Medical aesthetic platform integration:** Sisram acquired Foshion, one of the leading dental equipment sales and marketing platforms in Mainland China, and entered into a Sublicense Agreement with Fosun Industrial for the commercialization of the first long-lasting DaxibotulinumtoxinA product RT002 for the treatment of aesthetic indication.
- **Medical Diagnosis Segment Integration:** positioned each subsidiary with clear function to achieve strategy upgrade.
- Fosun Healthcare was renamed to **Fosun Health** and is upgrading to a comprehensive digital and online medical service platform.

Globalization

- The proportion of overseas revenue increased to **30.66% of the total revenue.**
- **Revenue for Gland Pharma increased by 32.08%* YoY.** The construction of "Sputnik V" COVID-19 vaccine line is in progress.
- Entered into a license agreement with Kintor Pharma to commercialize **Proxalutamide** for COVID-19 in India and 28 African countries.

Business Focus

- **Non-core assets disposal:** disposed Foshan Chanxi, a project company established for developing the "Chancheng Medical Health City Complex Project".
- **Asset structure optimization** : disposed Tianjin Pharma with a consideration of RMB1,433 million for 25% equity interest.

Note: According to Gland Pharma's financial statement

FOSUN PHARMA
Innovation for Good Health

Financial Results Overview

Key Financials (RMB million)	1H20	1H21	YoY(%)
Revenue	14,028	16,952	*20.86*
Net profit attributable to shareholders	1,715	2,482	*44.77**
Net profit after one-off gain	1,304	1,570	*20.38*
Net operating cash flow	1,461	1,707	*16.79*
Basic EPS (Rmb/share)	0.67	0.97	*44.78*
R&D Expenditure	1,689	1,954	*15.69*
R&D Expense	1,204	1,562	*29.73*

Note: the increase of Net profit attributable to shareholders was mainly due to: 1) Growth contribution from new products; 2) Expansion of overseas business; 3) Gains from changes in the fair value of the shares of BioNTech.



Note: The agreement between the Group and Intuitive Fosun in relation to the transfer of distribution rights of Da Vinci surgical robotic systems in Mainland China, Hong Kong and Macau has expired at the end of 2020. Since 2021, the revenue from such business has been transferred to Intuitive Fosun. Revenue from Med Tech increased by 14.40% excluding the effects of the changes in such business.

FOSUN PHARMA
Innovation for Good Health

Results Overview

Revenue



Operating Cash Flow



Profit Attributable



Net profit after One-off Gain



Note: Operating cash flow shown above excluded the impact of the 125mn Euro upfront payment to BioNTech for the mRNA vaccine for COVID-19

FOSUN PHARMA
Innovation for Good Health

Operating Performance Analysis

Expense Structure	2019	2020	1H20	1H21
Gross Margin	*59.6%*	*55.7%*	*55.7%*	*52.2%*
Selling and Distribution	*34.4%*	*27.9%*	*28.0%*	*25.7%*
Administrative	*9.1%*	*9.8%*	*9.2%*	*8.6%*
R&D	*7.1%*	*9.2%*	*8.6%*	*9.2%*
Finance	*3.0%*	*2.4%*	*2.1%*	*1.7%*

Note: In 1H20, the decrease of gross margin was mainly due to: 1) the gross margin decrease of You Li Tong (febuxostat tablets) and Bang Zhi (pitavastatin calcium tablets) after being selected for volume-based procurement; 2) the price increase in relation to main raw and auxiliary materials of core products; 3) the impact of expiration in relation to distribution rights transfer agreement of Da Vinci surgical robotic system.

(RMB Million)

Operating Results



Operating Results Margins	1H20	1H21
Total Results Margin	*11.6%*	*10.3%*
Pharmaceutical	*11.1%*	*11.0%*
Med Tech	*19.3%*	*15.3%*
Healthcare Services	*2.3%*	*-1.1%*

Note: Operating results margins of Med Tech decreased by RMB760 mn or 14.90%. Operating results margins of Med Tech increased by 24.36% excluding the impact of expiration in relation to distribution rights transfer agreement of Da Vinci surgical robotic system

FOSUN PHARMA
Innovation for Good Health

Liquidity and Capital Structure

Current Ratio



Quick Ratio



Debt Ratio



Equity attributable to owners of Parent



FOSUN PHARMA
Innovation for Good Health

Contents



Pharmaceutical

Financial Results

Med Tech

Healthcare Service

Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

R&D – Differentiation and Internationalization

China's pharmaceutical industry is undergoing a transformation towards high-quality R&D encouraged by regulatory policies.

- **Quality Consistency Evaluation of generic drugs, centralized procurement and national level GPO**
- **Medical Insurance Payment Reform: generic names/DRGs**
- **Drug approval reform: acceleration of approval process for innovative and urgently needed drugs**
- **Dynamic adjustment of NRDL with negotiation mechanism**
- **Clinical value-oriented drug innovation**

With strict regulatory policies and the pressure on medical insurance from the pandemic, R&D entered into a new era of fierce competition.

R&D entered into a new era of fierce competition

Best-in-Class/Me-Better advantages
Clinical value-oriented drug innovation to create clinical advantages, expand the negotiation space and increase the commercial value.

Next generation of biotechnology to enhance differentiated competitive advantages
Exploring cutting-edge technologies to capture differentiated competitive advantages and promote industry development..

Overseas clinical trials for international innovation
Leveraging the overseas clinical resources to accelerate R&D, endorse product quality, and derive incremental value from overseas commercialization.

First-to-Follow: Faster than peers to capture more market share
Advanced generic drug development capability, accelerating product approval and commercialization to capture more market share.

FOSUN PHARMA
Innovation for Good Health

Pharma Segment Performance

Segment Revenue

(RMB million)



R&D

- Through independent R&D, co-development, in-license and incubation, focus on oncology immunology, four hypes (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, central nervous system and other major therapeutic areas.
- Build small molecule innovative drugs, antibody drugs, cell therapy platforms, and actively explore cutting-edge technology fields such as RNA, oncolytic viruses and gene therapy.

Segment Results

(RMB million)



Manufacture

- Domestic: Build comprehensive formulation manufacturing center, enhance specialty formulation manufacturing base, continue to expand production capacity of biological
- Overseas: Set Gland Pharma as front station to enhance manufacture system with international standard

Segment Profit

(RMB million)



Commercialization

- With the launch of innovative products, established the innovative drug commercialization team, the new retail team, the professional sales & marketing team in Africa, Europe and the US. A comprehensive support team is also constructed for medical affairs, market access and brand promotion purposes.
- Continuously enhance the construction and integration of the commercialization system, adhering to the guidance of professional, brand and digital development.

FOSUN PHARMA
Innovation for Good Health

Pharma Segment Growth Driver

The pharma segment maintained steady growth under the impact from Volume-based Procurement, with optimized product portfolio, mainly due to:

- Launches and sales ramp-up of new products: increased sales volume of Han Li Kang (Rituximab Injection) with revenue of RMB724 mn in 1H21, increased 223.21% YoY; Han Qu You (Trastuzumab injection) and Su Ke Xin (Avatrombopag Tablets) recorded revenue of RMB325 mn and RMB206 mn respectively in 1H21; the new specification (60mg/vial) of Han Qu You was approved by NMPA in August 2021, laying foundation for further sales increase;
- Gland Pharma's revenue increase 32.08%* YoY due to new product launches including Micafungin and Exnoxaparin injection;
- Comirnaty (COVID-19 mRNA vaccine) was distributed and administered in Hong Kong and Macau in 1H21, recorded revenue of over RMB500 mn;
- Sales revenue of Atomolan (Glutathione Tablet) increased 60.70% YoY, driven by optimized life cycle management and sales channel expansion.



- **Anti-tumor and immune modulation core products**: increase was mainly due to the revenue increase from Han Li Kang (rituximab injection), Han Qu You (trastuzumab injection) and Su Ke Xin (avatrombopag maleate tablets).
- **Metabolism and alimentary system core products**: decrease was mainly due to the decreased unit selling price of You Li Tong (febuxostat tablets) after the volume based procurement.
- **Anti-infection core products:** increase was mainly due to the revenue contribution from Comirnaty (mRNA COVID-19 vaccine) and the sales revenue increase of Micafungin.
- **Central nervous system core products:** decrease was mainly due to the combined effect of the sales decline of Ao De Jin (deproteinized calf blood injection), and the decreased unit selling price of Qi Wei (quetiapine fumarate tablets) after the execution of volume based procurement, partially offset by the growth in sales revenue of Chang Tuo Ning (penehyclidine hydrochloride injection)
- **Cardiovascular system core products:** decrease was mainly due to the decreased unit selling price of Bang Zhi (pitavastatin calcium tablets) after the execution of volume based procurement

Note: According to Gland Pharma's financial statement.

FOSUN PHARMA
Innovation for Good Health

R&D –Expenditure & Expense

R&D Expenditure & Expense

(RMB million)



Pharma R&D Expenditure & Expense

(RMB million)



- Established **Global R&D Centre** in early 2020 as an upgrade of internal R&D system, for overall pipeline management to enhance the efficiency of clinical study.
- Approximately **2,600** R&D staff employees (of which approximately **1,400** employees obtained a master's degree or above) – **7.45** % of the total number of Employees
- Strong R&D capabilities with **240** ongoing pipeline projects (not including Gland Pharma's pipeline)

FOSUN PHARMA
Innovation for Good Health

R&D – Diversified R&D System

- **With diversified R&D System, accelerating R&D transformation, driving the development and commercialization of innovative products.**

- Rituximab Injection
- Trastuzumab for Injection
- Adalimumab Injection
- SAF189
- FCN-338
- Orin1001



- Avatrombopag
- Opicapone
- Tenapanor
- DaxibotulinumtoxinA for Injection
- SurVaxM

- T-Cell Therapy
- Stem Cell Therapy
- mRNA Vaccine (COVID-19)

- GeCell Therapeutics(gene therapy)
- Oncolytic virus
- Individualized vaccine for cancer treatment(AC-NP)/Multispecific immunonano therapy(MINP)

FOSUN PHARMA
Innovation for Good Health

R&D – License in & Out

License-in

Successful global BD track record:

- Extensive global network through years of experience with operation of overseas subsidiaries, FOFs and collaboration with international partners;
- Over 20 years of operation experience in domestic healthcare market to increase value for our global partners

2018
- Avatrombopag from Dova
- Opicapone from Bial

2019
- Regenerative medicine: Stem cell therapy from ReNeuron

2020
- Avatrombopag approved for launch in China
- Opicapone exempted for Phase III clinical trial
- mRNA vaccine from BioNTech

License-out

Innovative Small Molecule Drug

- Fochon grant Lilly to develop, manufacture and commercialize BCL-2 inhibitor FCN-338 in regions except the greater China on 29th Oct 2020; Lily shall pay no exceeding **USD440 million** (including upfront payment of **USD40 million**, no exceeding **USD340 million** in development milestones and USD60 million in sales milestones.

Antibody-based Drug

- Granted Intas Pharmaceuticals in January 2021 to exclusive commercialize HLX02 in the US and Canada with upfront payment of **USD27 million** and no exceeding **USD13 million** in development milestones.
- Granted Accord to exclusive commercialize HLX02 in Europe and part of the Middle East, North Africa region and the Commonwealth of Independent States with upfront payment of **USD8 million** and no exceeding **USD32 million** in development and sales milestones.
- Granted KG Bion to exclusive commercialize HLX10 in Southeast Asia with upfront payment of **USD10 million** and no exceeding **USD672 million** in development and sales milestones.

Actively searching for collaboration opportunities with globally leading pharma player to unlock and maximize the commercial value of R&D outcomes.

FOSUN PHARMA
Innovation for Good Health

R&D – mRNA Vaccine

mRNA Vaccine

Safety and Efficacy

- **High Safety and Efficacy with extensive evidence**
- Worldwide multicenter phase III clinical trial indicates the vaccine is 95.06% effective as measured seven days after the second dose. Israel's real-world statistics support the safety and efficacy data from clinical trail.

R&D

- **Short R&D time needed for novel vaccine**
- The vaccine is authorized to use for the age group above 12 years old in the U.S., EU, etc.

Storage & Transportation

- **Required to be stored and transported at cryogenic temperature.**
- The FDA and the EMA authorized mRNA COVID-19 vaccine to be stored in the refrigerator at 2℃ to 8 ℃ for up to 1 month.

Manufacturing Capacity

- **Easy to expand production capacity**
- According to BioNTech 1H21 report, the potential capacity is up to 3 billion doses BNT162b2 by the end of 2021 and 4 billion doses in 2022

Challenges from ongoing pandemic:

Viral Variants:

The current vaccine is effective against SARS-CoV-2 variants. **Fosun Pharma has the right to all mRNA vaccines against COVID-19 from BioNTech.**

- Pfizer and BioNTech announced in-vitro studies on January 27th that demonstrate COVID-19 vaccine is effective to U.K. and South African variants.
- Pfizer and BioNTech published a research in New England Journal of Medicine (NEJM), which shows BNT162b2 is able to neutralize Brazilian variant.
- NEJM released a research on July 22nd showed **the effectiveness of two doses of BNT162b2 was 88% against Delta variant**. Another RW research published in NEJM showed that the effectiveness is 91% and the viral load is reduced by 40% if breakthrough infections happened.

Booster/Sequential Clinical Trials:

- According to the interim report of BioNTech, booster dose could prolong protection and further increase breadth of protection against SARS-CoV-2 variants, 5-8-fold for wild type; 15-21-fold for Beta variant; 5-11-fold for Delta variant; over 5-fold to people between 18 and 55 years old; over 11-fold for seniors between 65 and 80 years old.
- The Comiranty and CoronaVac sequential clinical trial is under conducted by Dr. HUNG Fan Ngai in Hong Kong.
- Other researcher-initiated booster/sequential clinical trials related to Comiranty is conducting in Singapore, Bahrain and Chile.

FOSUN PHARMA
Innovation for Good Health

R&D – mRNA Vaccine

Fosun Pharmaceutical Industrial and BioNTech entered into a Term Sheet in relation to the proposed setting up of a Joint Venture Company for manufacturing and commercialization of the COVID-19 Vaccine.

Fosun Pharmaceutical Industrial (FOSUN PHARMA 复星医药)

50%

Capital contribution in the aggregate amount of not more than USD100 mn in cash and/or in tangible or intangible assets (comprising plants and manufacturing facility)

BioNTech (BIONTECH)

50%

Contribution in intangible assets including licensing of the relevant manufacturing technology and know-how, at the value of not more than USD100 mn

Localized Manufacture and Commercialization

Manufacturing Facility

- The **potential capacity** is **up to 1 billion doses** of COVID-19 Vaccine per annum;
- **Reconstructing the plant in Jinshan, Shanghai** for vaccine manufacturing.

Technology Transfer

- Under the Term Sheet, BioNTech shall be responsible for **conducting technology licensing** through entering into a technology license agreement and **providing technology assistance**, and shall ensure **sufficient capable personnel** in connection therewith.

Commercialization

- The JV Company shall engage **the affiliate of Fosun Pharmaceutical Industrial** as the **Contract Sales Organization (CSO)**
- Serving as a complement to domestic vaccine to help form domestic immune barrier against COVID-19

Future Collaboration

- Fosun Pharmaceutical Industrial and BioNTech may **potentially expand collaboration into other infectious diseases and therapeutic areas based on the mRNA platform**, subject to the success of the vaccine in China.
- The JV shall have a **right of first refusal** with respect to the **production of any mRNA-based therapy or vaccine** with certain agreed exceptions.

Building comprehensive product portfolio against COVID-19 with efficient R&D to response to the strong demand of the pandemic

Testing

COVID-19 Diagnostic test kit & Biomedlab:
Seizing the opportunity of diagnostic test kit and diagnostic center business with efficient R&D

Prevention/Treatment

mRNA COVID-19 Vaccine:
Collaborating with BioNTech to develop mRNA COVID-19 vaccine and to help establish domestic immune barrier against COVID-19

Antibody Drug R&D and Proxalutamide:
Developing COVID-19 neutralizing antibodies and nano-antibodies with R&D platform(Henlius, Biomissile and Starmab); Entered into a license agreement with Kintor to commercialize Proxalutamide, a COVID-19 treatment, in India and 28 countries in Africa.

Note: By the end of 23th Aug 2021, the detail of setting up a Joint Venture is still under discussing.

R&D –T Cell Therapy Platform

Fosun Kite FOSUNKite 复星凯特生物

- The joint venture of Fosun Pharma and Kite Pharma (a Gilead Company) in Shanghai, dedicated in the R&D and industrialization of immuno cell therapies.
- Yi Kai Da® (Axicabtagene Ciloleucel Injection) is approved by NMPA in June 2021 **for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy**. It is **the first approved CAR-T cell therapy in China**.
- Yi Kai Da® has been granted **breakthrough therapy designation** in August 2021 by NMPA for the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma (r/r iNHL) after two or more lines systemic therapy, including follicular lymphoma (FL) and marginal zone lymphoma (MZL).
- Kite Pharma's Tecartus™ has been approved by FDA for the treatment of r/r MCL in July 2020. Technology transfer for this product commenced in China.

Clinical Trial

Result of ZUMA-1 Clinical Trial for Yescarta®

1 Year Post Infusion[1]

Overall Response Rate
- ORR: **82%**

Complete Response
- CR: **54%**

2 years Post Infusion[2]

Median of **27.1 mths**
Overall Response Rate
- ORR: **83%**

Complete Response
- CR: **58%**

Sustained Response
- SR: **39%**

≥ 4 years Post Infusion[2]

Median Overall Survival
- OS: **25.8 mths**

4 Years Overall Survival
- OS: **39%**

Multicenter Clinical Trial in China for Bridging Study:

- **The overall response rate (ORR) for Yi Kai Da® is 79.2%.**
- The safety and efficacy statistics for Yi Kai Da® is **highly similar** to the ZUMA-1 study and real-world statistics of Yescarta®

FOSUN PHARMA
Innovation for Good Health

Reference:
1.Nastoupil LJ, et al. 2018 ASH 2967.
2.Crump M, et al. Blood. 2017;130(16):1800-1808.

R&D – Incubation & Early-stage Investment



FOSUN PHARMA
Innovation for Good Health

R&D – In-house Development: Biopharmaceuticals Core Pipeline

	Product		Target	Indication
Near Commer-Cialization	HLX01(Rituximab)		CD20	Rheumatoid Arthritis
	HLX04(Bevacizumab)		VEGF	metastatic Colorectal Cancer / non-squamous Non-Small Cell Lung Cancer
	HLX10 Mono		PD-1	Microsatellite Instability-high Solid Tumors（MSI-H）
Clinical Stage	HLX10	+chemo	PD-1	metastatic Esophageal Carcinoma
				Squamous Non-Small Cell Lung Cancer
				Extensive Small Cell lung Cancer
				Gastric Cancer
		+HLX04	PD-1+VEGF	Non-squamous Non-Small Cell Lung Cancer
				Metastatic colorectal cancer
				Hepatocellular Carcinoma
		+HLX07	PD-1+EGFR	Squamous Cell Carcinoma of Head and Neck
	HLX07		EGFR	Solid tumor
	HLX05(Cetuximab)		EGFR	metastatic colorectal cancer (mCRC)/squamous cell carcinoma of the head and neck
	HLX12(Ramucirumab)		VEGFR2	Gastric cancer/ metastatic non small cell lung cancer/Mcrc
	HLX20		PD-L1	Solid tumor
	HLX22		HER2	Breast cancer/Gastric cancer
	HLX55		c-MET	Solid tumor
	HLX11(Pertuzumab)		HER2	Breast cancer
	HLX14(Denosumab)		RANKL	Osteoporosis
	HLX04-o		VEGF	wet Age-related Macular Degeneration
	HLX13(Ipilimumab)		CTLA-4	Melanoma/ Renal cell carcinoma, mCRC



Note: Clinical trial progress updated to Aug 23, 2021.

FOSUN PHARMA
Innovation for Good Health

R&D – Innovative Small Molecule Core Pipeline

- **Fochon** granted **Lilly** exclusive rights to develop and commercialize FCN-338 in all countries and regions excluding Mainland China, Macau and Hong Kong in Oct 2020. Lilly shall pay Fochon upfront payment of **USD40 million** and up to **USD400 million** in potential development and commercial milestones.

Therapeutic Area	Project	MOA	Indication	Pre-clinical / IND / Phase 1 / Phase 2 / Phase 3
Oncology	Furitinib succinate (FC-110/SAF-189)	ALK/ROS1	Late Stage NSCLC	Phase II approved in the US
	FCN-437	CDK4/6	Breast Cancer	Phase I in the US
	FN-1501	FLT3	Leukemia, Solid Tumor	Phase I in the US and AU
	Orin1001	-	r/r and metastatic Breast Cancer and advanced solid tumor	Phase I in the US
	FCN-159	MEK	Malignant melanoma Neurofibromatosis type 1	Phase I in the US
	FCN-647	BTK	Lymphoma	
	FCN-011	pan-TRK	NTRK fusion-positive solid tumors	
	FCN-338	BCL-2	Hematologic Malignancy	Phase I approved in the US
Metabolism and Digestive System	Wanbang SGLT-2 inhibitor	SGLT-2	Type II Diabetes	
	FCN-207	URAT1	Hyperuricemia / Gout	
Other	Orin103	-	Idiopathic pulmonary fibrosis	Phase I approved in the US

Note: Clinical trial progress updated to Aug 23, 2021.

FOSUN PHARMA
Innovation for Good Health

R&D – In-licensed Pharmaceutical Products

Therapeutic Area	Generic Name	Registration Category	Indication	Progress in China	Overseas Progress
Metabolism and Digestive System	Tenapanor Tablet	Chem 1	Irritable Bowel Syndrome with Constipation	Phase I	Launched in the US
	Ferric Pyrophosphate Citrate	Chem 5.1	Iron replacement for HD patients	Phase III	Launched in the US Triferic (solution)
Oncology	SurvaxM injection	Chem 1	Severe Glioblastoma	Clinical trail application preparing	Phase III Multi Regional Clinical Trial (MRCT) preparing
Infectious Diseases	mRNA vaccine BNT162b2	Chem 1	COVID-19	Phase II	CMA, EUA or temporary authorization in more than 50 Countries
	PA-824	Chem 1.1	XDR – Tuberculosis MDR – Tuberculosis	Phase I	Launched in the US Pretomanid
Nervous System	Opicapone Capsule	Chem 5.1	Adult Parkinson's Patients	NDA accepted (Phase III exempted)	Launched in Europe Ongentys
Blood System	Avatrombopag Tablet	Chem 2.4	Idiopathic Thrombocytopenic Purpura	Phase III	Launched in the US, Europe
	Tenapanor Tablet	Chem 1	End-stage Renal Disease – Hemodialysis	Phase III	Completed phase III
Others	RT002	Bio 1	Moderate-to-Severe Glabellar Lines	Phase III	Launched in the US
			Cervical Dystonia	Phase III	Phase III
	Fortacin spray (Lidocaine Prilocaine spray)	Chem 5.1	Premature ejaculation	Phase III Clinical trial approved	Launched in Europe

Note: Clinical trial progress updated to Aug 23, 2021.

FOSUN PHARMA
Innovation for Good Health

Manufacturing – International manufacturing System

Overseas: International GMP certification

International Standard

- 10 productions lines of domestic member enterprises obtained the GMP certification of US FDA, EU, MHLW Japan and MOH Germany;
- Gland Pharma's production lines obtained GMP certifications from US, EU, Japan, Australia and other countries/regions. The validation of the new lyophilization line and hormone product line is in progress, laying a foundation for further expand the production capacity. The construction of Sputnik V, COVID-19 vaccine, production line is in progress.

Domestic capacity expansion and integration

Biopharmaceutical:

- Xuhui Facility: has **20,000 L** capacity and received EU GMP certificate.
- Songjiang Facility: Plant (1) with planned capacity of **24,000 L** aims to commence trial production in 2022; Plant (2) with planned capacity **36,000 L** is under construction.

Small Molecule Drugs:

- Integrated and constructed specialty formulation production sites in Changde, Xinyi and Changshou.
- Improving production efficiency by enhancing CMO management and establishing production management committee.
- The construction of comprehensive formulation production sites such as Wanbang and Yao Pharma is in progress. Chongqing site has the production capacity for lyophilized powder injection and oral formulation.

FOSUN PHARMA
Innovation for Good Health

Map source: https://www.zrzyst.cn/, Figure number: GS (2016) 1549

Commercialization - Commercialization System



FOSUN PHARMA
Innovation for Good Health

Contents

Med Tech

Financial Results

Pharmaceutical

Healthcare Service

Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Med Tech Segment Performance

Segment Revenue

(RMB million)



Segment Results

(RMB million)



Segment Profit

(RMB million)



Medical Devices

Aesthetic Field

- As the core medical aesthetic platform, sisram's business covers energy based medical aesthetic devices, professional dental devices and injectable, etc.

Respiratory Care

- Exploiting home/hospital used respiratory devices market through Breas

Professional Medical Device & consumables

- Including Da Vinci surgical robotic system, negative pressure ambulances and other professional medical device with lead position in their own field

Fosun Diagnosis

- Enforced and completed the integration of diagnosis business, and positioned subsidiary companies as R&D manufacturing center, differential device R&D platform, diagnostic service platform and device manufacturing site, so as to achieve strategy upgrade
- Providing comprehensive solutions including molecular diagnosis, immuno diagnosis, biochemical diagnosis, microbiological diagnosis, POCT, glycomics and mass spectrum diagnosis etc.

Note: The agreement between the Group and Intuitive Fosun in relation to the transfer of distribution rights of Da Vinci surgical robotic systems in Mainland China, Hong Kong and Macau has expired at the end of 2020. Since 2021, the revenue from such business has been transferred to Intuitive Fosun. Revenue from Med Tech increased by 14.40% excluding the effects of the changes in such business.

FOSUN PHARMA
Innovation for Good Health

Medical Devices – Sisram Medical

Sisram Medical is the leading provider of energy-based surgical and medical aesthetic solutions and has comprehensive in-house capability with R&D, manufacturing, marketing and sales. Sisram owns flagship family systems such as Soprano for hair removal, Accent for skin tightening, Harmony for skin rejuvenation etc. Sisram is building its medical aesthetic ecosystem by enhancing EBD business and extending business branches in aesthetic dentistry and injectables.

1H21 Strong Performance

- Revenue and net profit increased significantly due to the strong performance in core markets, including North America and China. Compared to the pre-COVID level in 1H19, revenue and net profit increased 46.7% and 25.2%, respectively.
- Launched 2 innovative products in 1H21:

1) Body contouring and skin tightening platform Alma PrimeX, combining Alma's patented Ultrasound and patented UniPolar Radiofrequency to provide non-invasive treatment.

2) Alma Duo, a revolutionary treatment for men, using low-intensity extracorporeal shock wave therapy (LI-ESWT) to stimulate better blood flow.



Medical Aesthetic Ecosystem

- Aiming to **establish a synergistic medical aesthetic ecosystem** by focusing on the energy-based devices business unit, extending business branches with in-house R&D and external collaboration and exploring potential synergies among different business units.
- Exploring multi strategic resources integration and collaboration with Fosun Pharma and Fosun group:

1) Completed the acquisition of Foshion, one of the leading dental equipment sales and marketing platforms in Mainland China , in July 2021, aiming to build comprehensive digital dentistry platform by leveraging Sisram's global resources and channels.

2) Entered into a Sublicense Agreement with Fosun Industrial for the commercialization of the first long-lasting DaxibotulinumtoxinA product RT002 for the treatment of aesthetic indications in Greater China and continuously expanding injectables portfolio.

FOSUN PHARMA
Innovation for Good Health

Note: the sublicense is subject to approval of the Independent Shareholders

Medical Devices – Respiratory and Professional Medical Device & Consumables

Respiratory Care

BREAS

Z1 portable continuous positive airway pressure (CPAP) machine:
The smallest, lightest, most portable cpap machine (259g)

iSleep home-used series non-invasive ventilator:
Integrate humidification and constant temperature function

Vivo series medical respiratory devices:
Multi-function respiratory devices, for home/hospital use

Professional Medical Device & Consumables

INTUITIVE FOSUN 直观复星

- At the end of 2020, **5,989** da Vinci surgical systems were installed globally, including **3,720** in the US, **1,059** in Europe, **894** in Asia and **316** in the rest of the world; in the Asia-Pacific region, especially China, it is still in the early stage and has huge market potential;
- As of 30th June 2021, **6,335** da Vinci surgical systems were installed globally;
- **42 Da Vinci surgical robotic systems were installed in the first half of 2021.**

CHINDEX

JIANYOUCHENGYE

Covering multiple professional devices including imaging equipment, ambulances and hair transplant robots, etc.

- EOS® Whole Body Bone 3D Modeling Imaging System

- BodyTom® portable full body CT systems

- ARTAS Hair Transplant Surgical Auxiliary Robot

- Negative Pressure Ambulances

FOSUN PHARMA
Innovation for Good Health

Medical Diagnosis

Medical Diagnosis

- **Molecular Diagnosis**
- **Immuno-diagnosis**
- **Biochemical Diagnosis**
- **Microbiological Diagnosis**
- **POCT**
- **Mass Spectrometry Diagnosis**

- Enforced and completed the integration of diagnosis business, and positioned subsidiary companies as R&D manufacturing center, differential device R&D platform, diagnostic service platform and device manufacturing site, so as to achieve strategy upgrade
- Providing comprehensive solutions including molecular diagnosis, immuno diagnosis, biochemical diagnosis, microbiological diagnosis, POCT, glycomics and mass spectrum diagnosis etc.
- In 1H21, new products such as F-i3000 fully automated chemiluminescence instrument, F-C800 fully automated biochemical analyzer and microbial mass spectrometer (ASTA) were launched successively. The product pipeline included diagnostic products with high clinical value such as Glycotest HCC Panel (early liver cancer diagnosis and screening solution) and Volition (bowel cancer early screening and prognostic testing solution).

FOSUN PHARMA
Innovation for Good Health

Contents



1 Financial Results

2 Pharmaceutical

3 Med Tech

4 Healthcare Service

5 Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Healthcare Service Segment Performance

Segment Revenue

(RMB million)



- **Fosun Healthcare** was renamed to **Fosun Health**, providing users with one-stop healthcare services based on medical-grade trust and closed-loop solutions throughout the treatment course;
- Affected by increased investments in digital and online operation, the initial loss of newly opened hospitals and other factors, in 1H21, segment results amounted to RMB -19 million, representing a year-on-year decrease of RMB50 million. Segment profit amounted to RMB -15 million, representing a year-on-year decrease of RMB17 million.

Pioneer in providing regional healthcare services with the help of science and the internet

12 Specialty Departments: O.B., Cardiology, Neurology, Respiratory, Rehabilitation, Oncology, Orthopaedics, Clinical laboratory, Nursing, Nephrology, Pediatrics, Chinese Medicine

Establishing digital and online medical service platform with 6 hospitals acquiring internet hospital licenses up to now.

Pearl River Delta

- Expand healthcare services from **Foshan Chancheng Hospital and Shenzhen Hengsheng Hospital**; increase the regional impact

Yangtze River Delta

- **Collaborate with hospitals affiliated with Fudan University** and provide services over Shanghai, Zhejiang and southern part of Jiangsu

Cheng-Yu District

- Build the service chain based on **Chongqing Xiongrong Aesthetic Hospital** and expend gradually to other specialized services

FOSUN PHARMA
Innovation for Good Health

Contents



1 Financial Results

2 Pharmaceutical

3 Med Tech

4 Healthcare Service

5 Corporate Strategy

FOSUN PHARMA
Innovation for Good Health

Development Strategy

- Focus on the core field
- R&D is in compliance with the strategy
- Efficient capital investment and management
- Global collaboration

INnovation

INternationalization

- Solidify the industry status in China
- Build a globally-competitive pipeline
- Customized commercial team in the U.S., African, Indian and European markets
- Global supply chain management



INtelligentization

- Integrate different segments and platforms
- Enhance the efficiency and quality of R&D
- Upgrade manufacturing and quality monitoring system
- Increase marketing & sales capability in key platforms

INtegration

- Digital management capability improvement
- Digitalized R&D, manufacture and commercialization
- Resources and technologies to build smart hospital
- Ongoing digital innovation

FOSUN PHARMA
Innovation for Good Health

Strategic Planning of Segment Businesses

Pharma

R&D

- Through in-house R&D, co-development, in-license and incubation, focus on **oncology and immunology, four hypers (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, central nervous system** and other major therapeutic areas
- Build small molecule innovative drugs, antibody drugs, cell therapy platforms, actively explore cutting-edge technology fields such as RNA, oncolytic viruses and gene therapy

Manufacture

- Build **comprehensive formulation** manufacturing center, enhance **specialty formulation** manufacturing base, continue to expand production **capacity of biologic drugs**
- Set Gland Pharma as front station to enhance manufacture system with **international standard**

Commercialization

- With the launch of innovative products, established the **innovative drug commercialization team**, the **new retail team**, the professional sales & marketing team in **Africa, Europe and the US**. A comprehensive support team is also constructed for **medical affairs**, **market access** and **brand promotion**
- Continuously enhance the construction and integration of the commercialization system, adhering to the guidance of professional, branding and digital development

Medical Devices

- **Medical Aesthetic:** As the major medical aesthetic platform, sisram's business covers energy based medical aesthetic devices, professional dental devices and injectable, etc.
- **Respiratory Care:** Exploiting home/hospital used respiratory devices market through Breas
- **Professional Medical Device & Consumables:** Including Da Vinci surgical robotic system, negative pressure ambulances and other professional medical device with leading position in their own field

Medical diagnosis

- Enforced and completed the **integration of diagnosis business** to achieve strategy upgrade
- Providing comprehensive solutions including **molecular diagnosis, immuno diagnosis, biochemical diagnosis, microbiological diagnosis, POCT, glycomics and mass spectrum diagnosis** etc.

Healthcare Service

- A total of **13** holding hospitals with **4,732** beds, covering **Pearl River Delta, Yangtze River Delta** and **Cheng-Yu District**, building the Regional flagship hospitals including Foshan Chancheng and Shenzhen Hengsheng.
- Fosun Healthcare is renamed to Fosun Health, and is upgraded to establish **comprehensive digital medical services platform.**

FOSUN PHARMA
Innovation for Good Health

Environmental, Social and Governance

- Environmental, Social and Governance (ESG) reflects a company's potential for sustainable growth in aspect of environmental protection, social responsibility and corporate governance.
- ESG became an increasingly import factor for evaluating a company's value while regulators issued higher requirements on ESG disclosure for listed companies.
- Fosun Pharma responded actively. In 2020, ESG Committee was established at Board Level.
- By the end of 2020 Fosun Pharma's MSCI ESG rating was improved **from BB to BBB**.

FOSUN PHARMA
Innovation for Good Health

Disclaimer and copyright

- 本文件中所包含的所有内容(包括预测性描述)，复星医药、陈述人或提供人不保证其完全准确、完整或及时，如因有关内容存在错误、遗漏或失准之处而引致的行为或结果，复星医药、陈述人或提供人对此不承担责任。
- 本文件内容不包含亦不应被视为任何投资建议，投资者基于本文件中内容做出的投资决策，责任自负。
- 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有，其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意，任何第三方不得以包括转载在内的任何方式加以使用。
- Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.
- The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.
- Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and”复星” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA
Innovation for Good Health

FOSUN PHARMA

复星医药

持续创新 · 乐享健康

复星医药微信公众平台

www.fosunpharma.com